Chemistry:Cibinetide

From HandWiki

Cibinetide (INN; USAN; developmental code name ARA-290) is an erythropoietin receptor agonist which is under development for the treatment of a variety of different medical conditions.[1][2][3][4] It was also under development for the treatment of depressive disorders, but development for this indication was discontinued.[1] The drug is under development by Araim Pharmaceuticals.[1][2] Modified derivatives with a longer duration of action have also been developed.[5]

References

  1. ↑ 1.0 1.1 1.2 "Cibinetide - Araim Pharmaceuticals". 28 June 2022. https://adisinsight.springer.com/drugs/800035038. 
  2. ↑ 2.0 2.1 "Delving into the Latest Updates on Cibinetide with Synapse". 8 October 2024. https://synapse.patsnap.com/drug/c4639d40db674d34b3ad283c50f0cfa7. 
  3. ↑ "Erythropoietin and its derivatives: from tissue protection to immune regulation". Cell Death Dis 11 (2). February 2020. doi:10.1038/s41419-020-2276-8. PMID 32015330. 
  4. ↑ "A small erythropoietin derived non-hematopoietic peptide reduces cardiac inflammation, attenuates age associated declines in heart function and prolongs healthspan". Frontiers in Cardiovascular Medicine 9. 2023. doi:10.3389/fcvm.2022.1096887. PMID 36741836. 
  5. ↑ "The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury". International Immunopharmacology 138. 2024. doi:10.1016/j.intimp.2024.112452. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Cibinetide&oldid=4310134"